發(fā)布時間：2018-05-14 11:39

  本文選題：�？颂婺� + 肺癌��； 參考：《川北醫(yī)學院》2017年碩士論文

【摘要】：目的:初步探討鹽酸�？颂婺釋Ψ伟┘毎脑鲋骋种谱饔门cEGFR基因突變狀態(tài)的關系,為臨床上細胞藥敏試驗作為EGFR-TKIs療效預測方法之一提供參考。方法:以體外培養(yǎng)的A549和HCC827肺癌細胞株為實驗對象,通過形態(tài)學觀察和免疫細胞化學染色法鑒定兩細胞株,采用x TAG液相芯片技術檢測細胞株EGFR基因突變狀態(tài),CCK-8法檢測�？颂婺釋杉毎甑脑鲋骋种谱饔�,Annexin V-FITC/PI雙染法檢測�？颂婺釋杉毎甑拇俚蛲鲎饔�,實驗數(shù)據(jù)應用SPSS21.0軟件進行統(tǒng)計學分析,檢驗水準為P0.05。結果:1)兩細胞株形態(tài)學表現(xiàn)和免疫細胞化學染色情況均符合A549和HCC827肺癌細胞株的特性。2)EGFR基因突變狀態(tài):A549細胞株為野生型,HCC827細胞株為19外顯子缺失突變型(p.E746_A750del)。3)�？颂婺釋549細胞株作用48h的半數(shù)抑制濃度(IC50)為9.65±0.78μmol/L,對HCC827細胞株作用的IC50為0.12±0.01μmol/L,兩者比較差異有統(tǒng)計學意義(P=0.000)。4)選用0.1μmol/L鹽酸埃克替尼作用A549和HCC827細胞株48h,兩者細胞抑制率分別為0和(45.31±1.33)%(P=0.000),細胞凋亡率分別為(1.81±0.47)%和(62.25±2.45)%(P=0.000);選用1μmol/L鹽酸�？颂婺嶙饔肁549和HCC827細胞株48h,兩者細胞抑制率分別為(18.95±0.78)%和(75.53±2.98)%(P=0.000),兩者細胞凋亡率分別為(39.91±2.04)%和(89.26±3.81)%(P=0.000)。結論:1)本課題初步證實了免疫細胞化學染色鑒定A549和HCC827肺癌細胞株的可行性,研究中的免疫細胞化學染色結果可能成為其他研究中鑒定該兩細胞株時的參考依據(jù);2)課題中�？颂婺釋GFR基因突變型的HCC827肺腺癌細胞株的增殖抑制作用明顯強于EGFR基因野生型的A549肺癌細胞株,提示研究方法真實、可靠,可為臨床上EGFR-TKIs細胞藥敏試驗的實施提供一定參考。
[Abstract]:Objective: to investigate the relationship between the inhibitory effect of Ektinib hydrochloride on the proliferation of lung cancer cells and the mutation status of EGFR gene, and to provide a reference for clinical chemosensitivity test as one of the methods for predicting the curative effect of EGFR-TKIs. Methods: A549 and HCC827 lung cancer cell lines were cultured in vitro and identified by morphological observation and immunocytochemical staining. X TAG liquid chip technique was used to detect the mutation status of EGFR gene in cell line and CCK-8 method was used to detect the inhibitory effect of Ectini on the proliferation of two cell lines. Annexin V-FITC/PI double staining was used to detect the apoptosis-promoting effect of Ectini on the two cell lines. The experimental data were analyzed by SPSS21.0 software, and the test level was P0.05. Results the morphological features and immunocytochemical staining of the two cell lines were consistent with the characteristics of A549 and HCC827 lung cancer cell lines. IC50 was 9.65 鹵0.78 渭 mol / L in A549 cell line and 0.12 鹵0.01 渭 mol / L in HCC827 cell line for 48 h. The difference was statistically significant (P < 0.05). The inhibition rate of A549 cell line and HCC827 cell line treated with 0.1 渭 mol/L epetinib hydrochloride for 48 h was significant. The cell apoptosis rates were 1.81 鹵0.47% and 62.25 鹵2.45%, respectively, and the inhibitory rates of 1 渭 mol/L hydrochloride on A549 and HCC827 cells for 48 h were 18.95 鹵0.78% and 75.53 鹵2.98%, respectively, and the apoptotic rates were 39.91 鹵2.04% and 89.26 鹵3.81%, respectively. Conclusion 1) the feasibility of identification of A549 and HCC827 lung cancer cell lines by immunocytochemical staining was preliminarily confirmed. The results of immunocytochemical staining in the study may be the reference basis for identifying the two cell lines in other studies. The inhibitory effect of Ectini on the proliferation of EGFR mutant HCC827 lung adenocarcinoma cell lines is significantly stronger than that of other studies. EGFR gene wild-type lung cancer cell line A549, The results suggest that the research method is true and reliable, and can provide some reference for the clinical application of EGFR-TKIs cell drug sensitivity test.
【學位授予單位】：川北醫(yī)學院
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R734.2

【參考文獻】

相關期刊論文 前10條

1 畢峰瑞;顏宏利;;循環(huán)腫瘤細胞檢測研究進展:從單純計數(shù)到表型與功能分析[J];中國腫瘤生物治療雜志;2017年04期

2 張文麗;孔凡虹;賀文艷;李奇;李昊文;董成亞;劉麗;何露;王雅杰;;細胞培養(yǎng)實驗中細胞系鑒定及質(zhì)量控制重要性探討[J];標記免疫分析與臨床;2017年01期

3 張鳳久;張麗敏;林安嶺;彭向東;劉兵;楊建玲;于玲燕;王海明;;視網(wǎng)膜血管內(nèi)皮細胞高糖模型糖濃度及培養(yǎng)時間的篩選[J];國際眼科雜志;2017年01期

4 吳文君;王智華;王卓;鄧宇亮;施奇惠;;肺癌患者外周血中循環(huán)腫瘤細胞的快速分離與體外培養(yǎng)[J];遺傳;2017年01期

5 楊蕊;唐秋莎;;CD90~+肝癌干細胞的鑒定及靶向治療研究[J];南京醫(yī)科大學學報(自然科學版);2016年10期

6 李婷;賈鈺銘;雷開鍵;;體外腫瘤細胞藥敏試驗方法概述[J];現(xiàn)代腫瘤醫(yī)學;2016年05期

7 Qian Ding;Xiang-Guo Tian;Yan Li;Qi-Zhi Wang;Chun-Qing Zhang;;Carvedilol may attenuate liver cirrhosis by inhibiting angiogenesis through the VEGF-Src-ERK signaling pathway[J];World Journal of Gastroenterology;2015年32期

8 劉標;周曉軍;;非小細胞肺癌免疫組化標志物專家共識(2014)[J];臨床與實驗病理學雜志;2015年05期

9 王愛平;李嚴兵;謝巍;曹宇輝;彭田紅;周小兵;龔邵新;;酶消化法分離培養(yǎng)原代肺動脈平滑肌細胞及免疫組化鑒定[J];中南醫(yī)學科學雜志;2015年01期

10 李賁;郭志敏;周雪;王云;董志偉;王琳;臧永坤;;非小細胞肺癌體外抗腫瘤藥物敏感性研究[J];醫(yī)學臨床研究;2014年12期

，

本文編號：1887709